Current issues in the management and monitoring of hypertension in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 6, 2013, Pages 599-606

  Garimella, Pranav S ^a   Uhlig, Katrin ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

blood pressure target; chronic kidney disease; chronotherapy; evaluation; hypertension; obesity

Indexed keywords

ALISKIREN; CREATININE; RAMIPRIL; SITAXSENTAN; SODIUM; TETRAHYDROLIPSTATIN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CHRONOTHERAPY; CLINICAL EVALUATION; COMORBIDITY; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DIURETIC THERAPY; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; HYPEROXALURIA; HYPERTENSION; KIDNEY INJURY; LIFESTYLE MODIFICATION; NEPHROLITHIASIS; OBESITY; OXALOSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SELF EXAMINATION; SODIUM RESTRICTION; SPECTROSCOPY; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DIELECTRIC SPECTROSCOPY; DIET, SODIUM-RESTRICTED; DRUG CHRONOTHERAPY; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; WEIGHT REDUCTION PROGRAMS;

EID: 84887026100     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328365addf     Document Type: Review

References (55)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
2. Ridao N, Luno J, Garcia de Vinuesa S, et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001; 16 (Suppl 1):70-73.
3. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
4. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35:539-543.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012; 2:337-414.
6. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. (NICE Clinical Guidelines, No. 127). London, UK: Royal College of Physicians; 2011; http://www.ncbi.nlm.nih.gov/books/NBK83274/ [Accessed 26 June 2013]
7. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013; 29:528-542.
8. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 2013; 36 (Suppl 1):S11-S66.
9. Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010; 28:2036-2045.
10. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348:2407-2415.
11. Hypertension: Evidence Update March 2013: a summary of selected new evidence relevant to NICE clinical guideline 127 'Clinical management of primary hypertension in adults' (2011). London, UK: Royal College of Physicians; 2013.
12. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011; 342: d286.
13. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1):S1-S290.
14. Hermida RC, SmolenskyMH, Ayala D E, Portaluppi F. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int 2013; 30:355-410.
15. Gorostidi M, Sarafidis PA, de la Sierra A, et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693- patient cross-sectional analysis from Spain. Am J Kidney Dis 2013; 62:285-294.
16. Wang C, Zhang J, Liu X, et al. Reversed dipper blood-pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic kidney disease. PloS one 2013; 8:e55419.
17. Uhlig K, Balk EM, Patel K, et al. Self-measured blood pressure monitoring: comparative effectiveness. Rockville, MD: Agency for Healthcare Research and Quality (US); 2012.
18. Rifkin DE, Abdelmalek JA, Miracle CM, et al. Linking clinic and home: a randomized, controlled clinical effectiveness trial of real-time, wireless blood pressure monitoring for older patients with kidney disease and hypertension. Blood Press Monit 2013; 18:8-15.
19. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 2013; 310:46-56.
20. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
21. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877-884.
22. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
23. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939-946.
24. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154:541-548.
25. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142:342-351.
26. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
27. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013; 185:949-957.
28. Wuhl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639-1650.
29. Hayashi K, Saruta T, Goto Y, Ishii M. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res 2010; 33:1211-1220.
30. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
31. ClinicalTrials.gov. SPRINT (Systolic Blood Pressure Intervention Trial). Clinical trial. [database on the Internet]. www.clinicaltrial.gov/ct2/show/ NCT01206062?term=SPRINT&rank=2on. [Accessed 1 July 2013]
32. ClinicalTrials.gov. HALT Progression of Polycystic Kidney Disease (HALT PKD). Clinical trial [database on the Internet]. www.clinicaltrial.gov/ct2/show/ NCT00283686?term=HALT-PKD&rank=1. [Accessed 1 July 2013]
33. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22:2313-2321.
34. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011; 34:1270-1276.
35. Almirall J, Comas L, Martinez-Ocana JC, et al. Effects of chronotherapy on blood pressure control in nondipper patients with refractory hypertension. Nephrol Dial Transplant 2012; 27:1855-1859.
36. Rahman M, Greene T, Phillips RA, et al. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension 2013; 61:82-88.
37. Crepaldi C, Soni S, Chionh CY, et al. Application of body composition monitoring to peritoneal dialysis patients. Contrib Nephrol 2009; 163:1-6.
38. Verdalles U, de Vinuesa SG, Goicoechea M, et al. Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). Nephrol Dial Transplant 2012; 27 (Suppl 4):iv31-iv35.
39. Sakai Y, Otsuka T, Ohno D, et al. Efficacy of aliskiren in Japanese chronic kidney disease patients with hypertension. Ren Fail 2012; 34:442-447.
40. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant 2011; 26:2930-2934.
41. Dhaun N, MacIntyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57:772-779.
42. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73:447-454.
43. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82:330-337.
44. Vegter S, Perna A, Postma MJ, et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23:165-173.
45. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17:1453-1459.
46. Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41:480-487.
47. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867-1872.
48. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46:871-880.
49. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65:1870-1876.
50. MacLaughlin HL, Cook SA, Kariyawasam D, et al. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis 2010; 55:69-76.
51. MacLaughlin HL, Sarafidis PA, Greenwood SA, et al. Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease. Am J Hypertens 2012; 25:1024-1029.
52. Courtney AE, O'Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007; 22:621-623.
53. Navaneethan SD, Kirwan JP, Arrigain S, et al. Overweight, obesity and intentional weight loss in chronic kidney disease: NHANES 1999-2006. Int J Obes (Lond) 2012; 36:1585-1590.
54. Kramer H, Tuttle KR, Leehey D, et al. Obesity management in adults with CKD. Am J Kidney Dis 2009; 53:151-165.
55. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145-154.